Chronic infections and lung inflammation play a significant role in the quality of life of persons with cystic fibrosis (CF) and the use of antibiotics may not be sufficient to fight bacterial infections in CF. The identification of new therapeutic options to replace or supplement antibiotics is highly desirable. This project is focused on the identification of probiotics, live microorganisms that can bring health benefits. The project aims to select, among the commercial probiotics, those most suitable for use in CF. The researchers will use experimental models to evaluate the action of probiotics by administering to cultures of pathogenic bacteria isolated from the sputum of persons with CF. The inhibitory capacity of probiotic bacteria on the replication and growth of pathogenic bacteria will be considered. In addition, the expression of virulence factors (eg digestive enzymes) playing an important role in lung tissue damage will be also measured. The most promising probiotics will be studied for their ability to protect human cells from cytotoxic effects and inflammation mediated by pathogenic bacteria.

XIX Convention FFC Ricerca – download here a brief presentation of the project